SCHEMBL20938345

SCHEMBL20938345

Nc1ncnc2c1c(-c1ccc(Cl)c(F)c1)cn2[C@@H]1O[C@H](CO)C[C@H]1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.47
▸ WDR77 Q9BQA1 1/20 0.47
▸ RIPK2 O43353 1/20 0.47
▸ ADK P55263 4/20 0.47
▸ SRC P12931 10/20 0.46
▸ KDR P35968 4/20 0.46
▸ RET P07949 3/20 0.46
▸ KIF5B P33176 3/20 0.46
▸ ABL1 P00519 2/20 0.46
▸ LCK P06239 2/20 0.46
▸ JAK2 O60674 1/20 0.46
▸ NTRK1 P04629 1/20 0.46
▸ INSR P06213 1/20 0.46
▸ NPM1 P06748 1/20 0.46
▸ CSF1R P07333 1/20 0.46
▸ LYN P07948 1/20 0.46
▸ IGF1R P08069 1/20 0.46
▸ MET P08581 1/20 0.46
▸ PDGFRB P09619 1/20 0.46
▸ KIT P10721 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20938344 0.93 ADK (0.47) RIPK2ADKSRCKDRRET
SCHEMBL20938267 0.92 ADK (0.49) ADKSRCKDRRETKIF5B
SCHEMBL20938343 0.92 RIPK2 (0.49) PRMT5WDR77RIPK2ADKSRC
SCHEMBL20938253 0.92 ADK (0.49) ADKSRCKDRRETKIF5B
SCHEMBL20938274 0.89 ADK (0.49) ADKSRCKDRRETKIF5B
SCHEMBL20920813 0.88 SRC (0.51) ADKSRCKDRABL1LCK
SCHEMBL20917259 0.88 RIPK2 (0.56) RIPK2ADKSRCKDRABL1
SCHEMBL20938250 0.88 SRC (0.51) ADKSRCKDRABL1LCK
SCHEMBL20938342 0.88 RIPK2 (0.56) RIPK2ADKSRCKDRABL1
SCHEMBL20938261 0.87 RET (0.57) RIPK2ADKSRCKDRRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072628-B2 Nucleoside analogues for the treatment of parasitic infections UNIVERSITEIT GENT (BE) 2021-07-27 — — US disclosed
US-20210024566-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS UNIVERSITEIT GENT (BE) 2021-01-28 — — US disclosed
WO-2019076633-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS UNIVERSITEIT GENT (BE) 2019-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072628-B2 Nucleoside analogues for the treatment of parasitic infections PNP, NUDT1, SAMHD1 PRMT5 716/4885WDR77 906/4885RIPK2 4326/4885
US-20210024566-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS PNP, NUDT1, SAMHD1 PRMT5 716/4885WDR77 906/4885RIPK2 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback